证券代码：430478 证券简称：峆一药业 公告编号：2024-005 2023 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 本人潘平作为安徽峆一药业股份有限公司（以下简称"公司"）的独立董 事，在任职期间严格按照《公司法》、《证券法》、《公司章程》、《北京证 券交易所股票上市规则（试行）》、《北京证券交易所上市公司持续监管指引第 1 号——独立董事》、《上市公司独立董事管理办法》等法律法规的规定和要求， 谨慎、认真、勤勉、独立地履行职责，持续关注公司规范运作、重大生产经营活 动、财务状况等，积极出席 2023 年度的相关会议，认真审议各项议案，对重 大事项发表了独立意见，维护了公司整体利益和全体股东尤其是中小股东的合法 权益。现就 2023年度任职期间内履行职责情况汇报如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 除独立董事之外的其他职务，也未在公司主要股东处担任任何职务；没有为公 司或其附属企业提供财务、法律、咨询等服务。除独立董事津贴外，没有 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《上市公司独立董事管理办法》、《北京证券交易所上市公司持续监 管指引第1号——独立董事》的规定，安徽峆一药业股份有限公司（以下简称" 公司"）董事会就公司在任独立董事潘平先生、冯乙巳先生、杨模荣先生的 2023 年度独立性情况进行评估并出具如下专项意见： 经核查独立董事潘平先生、冯乙巳先生、杨模荣先生的任职经历及其签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，亦未在 公司主要股东单位担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况， 符合《上市公司独立董事管理办法》等法律法规及《公司章程》中关于独立董 事独立性的要求。 证券代码：430478 证券简称：峆一药业 公告编号：2024-008 董事会关于独立董事独立性自查情况的专项报告 安徽峆一药业股份有限公司 董事会 2024 年 4 月 11 日 ...

国元证券股份有限公司 关于安徽峆一药业股份有限公司 募集资金投资项目延期的核查意见 国元证券股份有限公司（以下简称"国元证券"或"保荐机构"）作为安徽峆一 药业股份有限公司（以下简称"峆一药业"或"公司"）向不特定合格投资者公开发 行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《北京证券交易所 股票上市规则（试行）》《北京证券交易所上市公司持续监管办法（试行）》《北京 证券交易所证券发行上市保荐业务管理细则》《上市公司监管指引第 2 号—上市 公司募集资金管理和使用的监管要求》《北京证券交易所上市公司持续监管指引 第 9 号—募集资金管理》等有关法律、行政法规、部门规章及业务规则的要求， 对峆一药业募集资金投资项目延期情况进行了核查，核查的具体情况和核查意见 如下： 一、募集资金基本情况 2023 年 2 月 13 日，安徽峆一药业股份有限公司发行普通股 880 万股，发行 方式为向不特定合格投资者公开发行，发行价格为 12.62 元/股，募集资金总额为 11,105.60 万元，扣除发行费用 1,600.15 万元（不含税），募集资金净额为 9,505.45 万元，到账时间为 2023 年 2 月 ...

证券代码：430478 证券简称：峆一药业 公告编号：2024-015 安徽峆一药业股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 2023 年 1 月 5 日，经中国证券监督管理委员会《关于同意安徽峆一药业 股份有限公司向不特定合格投资者公开发行股票注册的批复》（证监许可〔2023〕 35 号）的核准，公司向不特定合格投资者公开发行不超过 1,012.00 万股新股（含 行使超额配售选择权所发新股）。公司本次发行价格为 12.62 元/股，发行股数 880.00 万股（不含行使超额配售选择权所发的股份），募集资金总额为人民币 11,105.60 万元（不含行使超额配售选择权所发的股份），扣除与发行有关的费 用人民币 1,600.15 万元（不含税）后，实际募集资金净额为人民币 9505.45 万 元（不含行使超额配售选择权所发的股份）。截至 2023 年 02 月 16 日，上述募 集资金已全部到账，并经容诚会计师 ...

" Rsm | 容 诚 募集资金存放与实际使用情况鉴证报告 安徽哈一药业股份有限公司 容诚专字[2024]230Z0094 号 容诚会计师事务所(特殊普通合伙) 中国 · 北京 安徽哈一药业股份有限公司全体股东: 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查 "。" 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 募集资金存放与实际使用情况鉴证报告 | | 1-3 | | 2 | 募集资金存放与实际使用情况的专项报告 | | 4-9 | 募集资金存放与实际使用情况鉴证报告 容诚专字[2024]230Z0094 号 我们审核了后附的安徽哈一药业股份有限公司(以下简称哈一药业)董事会编 制的 2023 年度《募集资金存放与实际使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供岭一药业年度报告披露之目的使用,不得用作任何其他目的。 我们同意将本鉴证报告作为哈一药业年度报告必备的文件,随其他文件一起报送 并对外披露。 二、董事会的责任 按照中国证券监督管理委员会《上市公 ...

Corporate Developments - The company was listed on the Beijing Stock Exchange on February 23, 2023[5]. - In June 2023, the company completed business registration changes and obtained a new business license[5]. - A wholly-owned subsidiary, Anhui Heryi Pharmaceutical Technology Co., Ltd., was established in October 2023[6]. - The company has expanded its consolidation scope to include 6 subsidiaries, an increase of 2 compared to the previous year[95]. - The company has actively participated in social responsibility initiatives, including donations to impoverished households and support for local economic development[97][98]. Intellectual Property and R&D - The company obtained two invention patents in September 2023 for high-yield synthesis methods of Lapatinib and Nilotinib[6]. - The number of patents owned by the company increased from 25 to 27, including an increase in invention patents from 6 to 8[85]. - R&D expenditure amounted to CNY 15,818,099.64, representing 6.99% of operating revenue, up from 6.43% in the previous year[82]. - The company has developed several core technologies, including amide reaction technology and "one-pot" production methods, aimed at improving production efficiency and reducing costs[188]. - The company is focused on continuous improvement in R&D, with a strong emphasis on product and process innovation[188]. Financial Performance - The company's operating revenue for 2023 was ¥226,253,170.32, a decrease of 12.54% compared to ¥258,700,268.97 in 2022[26]. - The net profit attributable to shareholders for 2023 was ¥48,572,460.01, down 14.10% from ¥56,546,533.07 in 2022[26]. - The gross profit margin for 2023 was 35.94%, a decline from 37.25% in 2022[26]. - Operating revenue for 2023 was ¥226,253,170.32, down 12.54% from ¥258,700,268.97 in 2022[56]. - The net profit attributable to shareholders was ¥48,572,460.01, a decline of 14.10% from ¥56,546,533.07 in the previous year, driven by reduced sales revenue[48]. Assets and Liabilities - Total assets increased by 40.05% to ¥533,395,393.75 in 2023, compared to ¥380,862,953.69 in 2022[28]. - The net asset attributable to shareholders rose by 47.46% to ¥455,799,065.23 in 2023, up from ¥309,106,451.08 in 2022[28]. - As of the end of 2023, cash and cash equivalents decreased by 14.02% to ¥68,776,270.48, compared to ¥79,993,985.09 at the end of 2022[53]. - Accounts receivable dropped by 51.53% to ¥15,759,180.82, primarily due to a decrease in operating income[54]. - Inventory increased by 35.83% to ¥91,503,549.77, attributed to increased stockpiling at the end of the period[54]. Market and Industry Trends - The raw material pharmaceutical industry is currently experiencing a downward cycle, impacting demand for antiviral products like biphenyl dimethyl ester[51]. - The global active pharmaceutical ingredient (API) market is benefiting from steady growth in downstream drug formulation demand, particularly due to the increasing number of patent expirations for innovative drugs, leading to a significant rise in the demand for generic drugs[101]. - China's API industry has transitioned from producing low-end bulk APIs to high-end specialty APIs, enhancing deep processing capabilities and improving drug quality, establishing a complete pharmaceutical intermediate industry system[102]. - The Contract Development and Manufacturing Organization (CDMO) business is rapidly developing, driven by the need to reduce new drug development costs and improve efficiency, with expectations for long-term growth in this sector[103]. Compliance and Governance - The company emphasizes strict compliance with environmental and safety production regulations, which may lead to increased operational costs in the future[50]. - The company has established a robust internal control system for revenue recognition, which is a critical audit matter due to inherent risks[89]. - The company ensures compliance with corporate governance standards to protect shareholder rights and enhance decision-making processes[135]. - The company will strictly adhere to laws and regulations to reduce and standardize related party transactions, ensuring the protection of the company's interests and normal operations[140]. Shareholder Commitments and Stock Management - The lock-up period for shares held by directors, supervisors, and senior management will automatically extend by 6 months if the stock price closes below the issue price for 20 consecutive trading days within 6 months post-listing[118]. - Controlling shareholders and actual controllers commit to not transferring more than 25% of their shares during their tenure and not transferring any shares within 6 months after leaving their positions[119]. - The company will publicly explain any failure to comply with the commitments made by shareholders and will compensate investors for any losses incurred due to such failures[120]. - The company commits to stabilizing its stock price within the first month of listing on the Beijing Stock Exchange if the closing price is below the issuance price for 10 consecutive trading days[125]. Employee and Management Structure - The company employed a total of 424 employees at the end of the reporting period, an increase of 58 from the beginning of the period[175]. - The number of management personnel increased from 16 to 22 during the reporting period[175]. - The company has implemented a comprehensive training program for employees to enhance their professional skills and management capabilities[176]. - The total remuneration paid to directors, supervisors, and senior executives during the reporting period amounted to 3.0742 million yuan[173]. Environmental and Safety Compliance - The company is committed to environmental protection, ensuring that emissions meet national standards and managing waste responsibly[99]. - The company has established a comprehensive safety production management system and equipped it with adequate safety facilities to mitigate risks associated with hazardous materials[109]. - The company has obtained environmental approval and ISO 14001:2015 certification, ensuring compliance with environmental regulations[199]. - There were no major safety or environmental incidents reported during the reporting period[199].

证券代码：430478 证券简称：峆一药业 公告编号：2024-002 容诚会计师事务所作为公司 2023 年度审计机构，原委派史少翔先生、宋世 林先生为公司提供审计服务，张良文先生为质量控制复核人。鉴于原签字注册 会计师史少翔先生、宋世林先生、原质量控制复核人张良文先生工作调整，现拟 将签字注册会计师更换为周文亮先生、吴玉娣女士、彭兵先生，将项目质量控 制复核人更换为蔡晓枫女士。本次变更后的签字注册会计师为周文亮先生、吴 玉娣女士、彭兵先生，质量控制复核人为蔡晓枫女士。 二、本次变更签字注册会计师、质量控制复核人的基本情况 （一）基本情况 项目合伙人：周文亮先生，2014年成为中国注册会计师，2008年开始从事上 市公司审计业务，2008年开始在容诚会计师事务所执业；近三年签署过斯迪克 （300806.SZ）、英力股份（300956.SZ）、五洲医疗（301234.SZ）等上市公司 审计报告。 关于变更签字注册会计师、质量控制复核人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 安徽峆一药业股 ...

Financial Performance - The company's operating revenue for 2023 was CNY 226,999,688.91, a decrease of 12.25% compared to the previous year[5] - Net profit attributable to shareholders was CNY 51,224,844.16, down 9.24% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 34,891,112.81, a decline of 32.14% compared to the previous year[5] - Basic earnings per share decreased to CNY 1.34, down 28.72% year-on-year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 535,502,865.11, an increase of 40.66% from the beginning of the period[5] - Shareholders' equity attributable to the company increased by 48.32% to CNY 458,339,701.92[5] - The company's capital stock increased by 33.69% to CNY 40,157,500.00[5] Market Conditions - The decline in revenue was primarily due to intensified domestic competition and reduced demand, leading to a decrease in sales of antiviral products by over CNY 13 million[6] Government Support - The company received government listing subsidies of CNY 12 million during the reporting period[6] Capital Increase - The increase in shareholders' equity and capital stock was mainly due to the company's listing on the Beijing Stock Exchange and the influx of raised funds[6]

| | 公告日期 2024-02-06 异常期间 无 | | | | | --- | --- | --- | --- | --- | | | 峆一药业(430478) 连续竞价 4141052 | 成交数量 | 成交金额（万 | 7536.4 | | | （股） | | 元） | | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | 买/卖 | 营业部或交易单元名称 | | 买入金额（元） | 卖出金额（元） | | 买1 | 东吴证券股份有限公司苏州西北街二部营业部 | | 3970966.08 | 0 | | 买2 | 中国银河证券股份有限公司威海统一路证券营业部 | | 3571854.89 | 0 | | 买3 | 平安证券股份有限公司深圳金田路证券营业部 | | 1828345.4 | 15216 | | 买4 | 中银国际证券股份有限公司中银天津分支 | | 1472477.34 | 0 | | 买5 | 浙商证券股份有限公司衢州衢化学院路证券营业部 | | 1370675.05 | 0 | | 卖1 | 华泰证券股份有限公司南京中央路第三证券营业部 | | 0 | 62 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-02- | | | | | 异常期间涨跌幅偏离值累计 | | 06 | 833454 | 同心传动 | 40358281.0 | 46105.5 | 达到63.58% | | 2024-02- | 837663 | 明阳科技 | 18864500.0 | 24413.58 | 异常期间涨跌幅偏离值累计 | | 06 | | | | | 达到51.32% | | 2024-02- | 873570 | 坤博精工 | 2748272 | 11043.36 | 当日收盘价涨幅达到30.00% | | 06 | | | | | | | 2024-02- | | 九菱科技 | | | 当日收盘价涨幅达到29.99% | | 06 | 873305 | | 3389123 | 5593.54 | | | 2024-02- | 833454 | 同心传动 | 22575674.0 | 29572.71 | 当日收盘价涨幅达到29.97% | | ...